ArticleMolecular cancer therapeutics2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 4 pooled it
16.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Pooled it
- Detection ofFrontiers in oncology · 2023Pooled it
- Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.PloS one · 2023Pooled it
- Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- The CRABP2-MDK Signaling Axis Promotes Lung Adenocarcinoma (LUAD) Progression and Highlights Prognostic Biomarkers.Molecular carcinogenesis · 2026Article
- Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Article
- The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine.International journal of molecular sciences · 2026Review
- TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776-Altered Subtype of HER2-Mutant NSCLC.Cancer science · 2026Article
- Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Virchows Archiv : an international journal of pathology · 2026Article
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- Three Rare Cases of Pulmonary Squamous Cell Carcinoma Harboring a KRAS Mutation, Including the Actionable G12C Variant.Pathology international · 2026Article
- The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2026Article
- Molecular Analysis of EBUS-TBNA Samples for Nodal Staging in Non-Small Cell Lung Cancer.Cancers · 2026Review
- LNA GapmeR silencing of KRAS G12V impairs growth and function in SW480 cells.Molecular and cellular biochemistry · 2026Article
- Sotorasib in AdvancedJTO clinical and research reports · 2026Article
- Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.Cancer discovery · 2026Article
- Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Functional analysis of the human miRNome in non-small cell lung cancer unveils a novel miR-92b-3p/NOTCH3 axis that drives tumor progression.Cell death & disease · 2026Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 16 institutions in 2 countries.
Julia JuddDepartment of Hematology-Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.
Nagla Abdel KarimDepartment of Hematology-Oncology, Augusta University-Medical College of Georgia, Georgia Cancer Center, Augusta, Georgia.
Hina KhanDepartment of Hematology-Oncology, The Warren Alpert Medical School, Brown University, Providence, Rhode Isand.
Abdul Rafeh NaqashDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-7622-720X
Yasmine BacaCaris Life Sciences, Phoenix, Arizona.
Joanne XiuCaris Life Sciences, Phoenix, Arizona.
Ari M VanderWaldeDepartment of Medical Oncology, West Cancer Center and Research Institute, Memphis, Tennessee.ORCID 0000-0002-6842-2563
Hirva MamdaniDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.ORCID 0000-0003-3874-8703
Luis E RaezDepartment of Hematology-Oncology, Memorial Cancer Institute/Memorial Health Care System/Florida International University, Hollywood, Florida.ORCID 0000-0003-2669-5771
Misako NagasakaDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.ORCID 0000-0001-5308-615X
Sachin Gopalkrishna PaiDepartment of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama.ORCID 0000-0002-6755-3895
Mark A SocinskiDepartment of Medical Oncology, AdventHealth Cancer Institute, Orlando, Florida.
Jorge J NievaDepartment of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0003-1605-4719
Chul KimDepartment of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.ORCID 0000-0003-0191-8684
Antoinette J WozniakDepartment of Medical Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Chukwuemeka IkpeazuDepartment of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, Florida.
Gilberto de Lima LopesDepartment of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, Florida.
Alexander I SpiraDepartment of Medical Oncology, Virginia Cancer Specialists, US Oncology Research, Fairfax, Virginia.
W Michael KornCaris Life Sciences, Phoenix, Arizona.ORCID 0000-0002-0124-6841
Edward S KimDepartment of Medical Oncology, City of Hope, Los Angeles, California.
Stephen V LiuDepartment of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.ORCID 0000-0002-4852-3914
Hossein BorghaeiDepartment of Hematology-Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania. hossein.borghaei@fccc.edu.
Caris Life Sciences (United States) · USGeorgetown University · USSylvester Comprehensive Cancer Center · USTemple University Health System · USThe Barbara Ann Karmanos Cancer Institute · USAugusta University · USBrown University · USCity Of Hope National Medical Center · USFlorida Hospital Cancer Institute · USMemorial Healthcare System · USOklahoma State University Oklahoma City · USUniversity of Pittsburgh Medical Center · USUniversity of Southern California · USUSA Mitchell Cancer Institute · USVirginia Cancer Specialists · USWest Cancer Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingHumansLung NeoplasmsMicrosatellite InstabilityMutationPrognosisProto-Oncogene Proteins p21(ras)KRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.